Core Viewpoint - Xintian Pharmaceutical (002873.SZ) has received approval from the National Medical Products Administration for clinical trials of Xinkang Capsules, aimed at treating cancer-related fatigue in colon cancer patients [1] Group 1: Company Developments - The approval allows Xintian Pharmaceutical to conduct clinical trials to validate the efficacy of Xinkang Capsules for treating cancer-related fatigue (CRF) [1] - Cancer-related fatigue is defined as a painful, persistent sense of exhaustion that cannot be alleviated by rest, often accompanied by cognitive impairment and emotional distress [1] Group 2: Industry Context - The clinical practice guidelines for cancer-related fatigue in China (2021 edition) outline the characteristics and impact of CRF on patients' daily lives [1]